Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5956442 | 0.89 | TGFBR1 (0.59) | TGFBR1MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL450076 | 0.88 | TGFBR1 (0.52) | TGFBR1MAPK14NPC1RAB9AMEN1 | |
| SCHEMBL5956501 | 0.86 | TGFBR1 (0.56) | TGFBR1MAPK14MEN1 | |
| SCHEMBL5956446 | 0.84 | TGFBR1 (0.61) | TGFBR1MAPK14THRB | |
| SCHEMBL5956677 | 0.83 | TGFBR1 (0.52) | TGFBR1MAPK14 | |
| SCHEMBL5956566 | 0.82 | TGFBR1 (0.52) | TGFBR1MAPK14 | |
| SCHEMBL5956486 | 0.81 | TGFBR1 (0.57) | TGFBR1MAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5956355 | 0.81 | TGFBR1 (0.67) | TGFBR1MAPK14MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5956378 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14NPC1RAB9AMEN1 | |
| SCHEMBL5956379 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004051-A1 | Compounds | DODIC NERINA | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004051-A1 | Compounds | SMAD3, SMAD2, TGFBR1 | TGFBR1 3/4885MAPK14 297/4885NPC1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.